Auvelity’s Early Alzheimer’s Agitation Launch Draws Bullish Analyst Notes
Mizuho, Needham and Guggenheim cite 32–34% script growth and robust 65+ uptake as Auvelity’s Alzheimer’s agitation launch gets off to a strong start.
/ 3 items
#AXSM↓
FDA Greenlights AUVELITY: First New Treatment for Alzheimer’s Agitation in Years
FDA approves AUVELITY to treat Alzheimer’s agitation, offering a safer, effective option to reduce distress and improve patient care.
FDA Fast-Tracks Review of New Alzheimer's Agitation Treatment
Axsome's AXS-05 gets FDA priority review for treating agitation in Alzheimer's patients, with decision expected by April 2026.